CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 209 enrolled
Drug / intervention
εPA-44biological
Likely dose
εPA-44 900μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02862106
NCT02862106Phase 2Completed
CompareCT.gov

Second Stage:Open-label Study of Therapeutic Hepatitis B Vaccine (Mimogen-based) in Treating Chronic Hepatitis B Patients

Chongqing Jiachen Biotechnology Ltd.·interventional·Posted Aug 10, 2016·Updated Aug 20, 2019

In Brief

A Phase 2 clinical trial evaluating εPA-44 for Chronic Hepatitis B. Completed, enrolled 209 participants across 9 sites.

Detailed Summary

The purpose is to evaluate efficacy and safety of therapeutic HBV vaccine (mimogen-based) treatment in chronic hepatitis B patients and to explore the most effective dosage and provide the rational for optimal dosing schedule.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis B
CountriesChina
CollaboratorsThird Military Medical University

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedAug 10, 2016
Enrollment StartSep 1, 2010
Primary CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 9.9 years ago

Interventions

εPA-44biological

subcutaneously injection of εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128